Zhong Lun Law Firm fields a considerable life sciences and healthcare workload with capabilities spanning the subsectors of new drugs, bioproducts, pharmaceuticals and gene editing, excelling at M&A, restructuring, capital markets and compliance matters. Practice head Changyu Fu is equipped to handle corporate and IP protection issues, as well as disputes involving international commerce, trade and cross-border investments. Shaun Gao is a key figure for complex private equity and venture capital transactions, while Jim Qiu has a particular focus on compliance and risk management for multinational and domestic enterprises. Yuru Zuo leverages her dual background in biology and law when advising biotechnology and pharmaceutical clients.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
- ‘Rigorous professional attitude, keen risk awareness and pragmatic solutions.’
- ‘The team has a deep understanding of laws, regulations and judicial practice in the fields of intellectual property rights and anti-unfair competition, and can quickly sort out the focus of disputes and provide a variety of rights protection solutions to clarify the direction for follow-up work.”
Key clients
- Tianjing Biotechnology Co., Ltd. Foreseen Biotechnology Valgen Holding Corporation RinuaGene Biotechnology Co., Ltd. Carlyle Group SynerK Biotechnology Co., Ltd LaNova Medicines Technology Co., Ltd. Dong-E-E-Jiao Co., Ltd. China Resources Biomedical Co., Ltd. Lepu Biopharma Co., Ltd. HTA Co., Ltd. Beijing Neurosurgical Institute Huaren Biotechnology Co., Ltd. Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. Beijing VAS Healthcare Technology Co., Ltd. Tibet Zhongwei Chengkang Pharmaceutical Co., Ltd. Vaccine And Health Institute Beijing Rencheng NeuroOncology Biotechnology Engineering Research Centre Co., Ltd. Beijing Jinwei Leping Pharmaceutical Technology Co., LTD Trial Data Pharmaceutical Technology Co., LTD Beijing Boyuanrunbu Pharmaceutical Development Co., LTD. Shenyang FORTUNE Precision Equipment Co., LTD Jianxin Equity Investment Management Co., Ltd.
Work highlights
Representing TJ Biopharma in its strategic collaboration with Sanofi regarding the development, manufacturing, and commercialisation of TJ Biopharma’s proprietary globally innovative CD73 antibody, Uliledlimab, in Greater China.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Next Generation Partners
Junior partners with significant recognition from clients and peers in the market and key roles on multiple matters.
Practice head
Helen Cheng; Changyu Fu; Dongmei Wang; Jim Qiu; Shaun Gao
Other key lawyers
Yuru Zuo; Qi Lan, Shuman Zhang; Chunhui Yan